Video

Dr. Ghosh on the Need to Develop Novel Therapies in DLBCL

Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.

Nilanjan Ghosh, MD, PhD, director, Lymphoma Program, physician, Levine Cancer Institute, discusses the need to develop novel therapies in diffuse large B-cell lymphoma (DLBCL).

Up to 70% of patients with DLBCL, as well as other aggressive large B-cell lymphomas, may derive a long-term remission or cure from standard frontline chemoimmunotherapy regimens, says Ghosh.

Autologous stem cell transplant (ASCT) should be considered for chemotherapy-sensitive patients who relapse, he adds.

However, some patients who relapse are ineligible for ASCT due to poor prognostic features or comorbidities, says Ghosh. As such, novel therapies to treat patients who are chemotherapy refractory and ineligible for transplant are needed.

CAR T-cell therapies including lisocabtagene maraleucel (liso-cel) may have utility in this space, concludes Ghosh.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity